{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:00:03Z","timestamp":1784034003506,"version":"3.55.0"},"reference-count":11,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013342","name":"NIHR Imperial Biomedical Research Centre","doi-asserted-by":"publisher","award":["Senior Investigator Award"],"award-info":[{"award-number":["Senior Investigator Award"]}],"id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","award":["MR\/T041285\/1"],"award-info":[{"award-number":["MR\/T041285\/1"]}],"id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:p>\n                    A common eligibility criterion in respiratory clinical trials is a per cent-predicted forced expiratory volume in 1 second (ppFEV\n                    <jats:sub>1<\/jats:sub>\n                    ) between 40% and 90%, using the ethnicity-dependent Global Lung Function Initiative (GLI)-2012 spirometry reference equations. International societies now endorse the newer \u2018race-neutral\u2019 GLI-Global equations. We quantify the impact on trial eligibility of switching from GLI-2012 to GLI-Global for the UK Cystic Fibrosis Registry (n=8182). In a future trial with a maximum eligibility threshold of ppFEV\n                    <jats:sub>1<\/jats:sub>\n                    =90%, the changes in ppFEV\n                    <jats:sub>1<\/jats:sub>\n                    would lead to over 700 people becoming newly ineligible. Urgent review of fixed ppFEV\n                    <jats:sub>1<\/jats:sub>\n                    thresholds is required, with an initial recommendation to widen the range to 30\u201395% ppFEV\n                    <jats:sub>1<\/jats:sub>\n                    when GLI-Global is implemented to ensure equitable access for people of all ethnicities. There is also a wider need to review the use of fixed ppFEV\n                    <jats:sub>1<\/jats:sub>\n                    spirometry limits for trial eligibility.\n                  <\/jats:p>","DOI":"10.1136\/thorax-2024-222652","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T17:20:24Z","timestamp":1757006424000},"page":"849-852","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Spirometry thresholds for clinical trial eligibility: time for urgent re-evaluation"],"prefix":"10.1136","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4945-5168","authenticated-orcid":false,"given":"Idan","family":"Bokobza","sequence":"first","affiliation":[{"name":"National Heart and Lung Institute, Imperial College London, London, UK"},{"name":"Clinical Trials Accelerator Platform, London, UK"},{"name":"Royal Brompton & Harefield NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Le Sayec","sequence":"additional","affiliation":[{"name":"Clinical Trials Accelerator Platform, London, UK"},{"name":"King\u2019s College Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"Bossley","sequence":"additional","affiliation":[{"name":"Clinical Trials Accelerator Platform, London, UK"},{"name":"King\u2019s College Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossa","family":"Brugha","sequence":"additional","affiliation":[{"name":"Clinical Trials Accelerator Platform, London, UK"},{"name":"Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3506-1199","authenticated-orcid":false,"given":"Jane Carolyn","family":"Davies","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Imperial College London, London, UK"},{"name":"Clinical Trials Accelerator Platform, London, UK"},{"name":"Royal Brompton & Harefield NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Dawson","sequence":"additional","affiliation":[{"name":"Clinical Trials Accelerator Platform, London, UK"},{"name":"Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Holt","sequence":"additional","affiliation":[{"name":"Clinical Trials Accelerator Platform, London, UK"},{"name":"Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic A","family":"Hughes","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Imperial College London, London, UK"},{"name":"Clinical Trials Accelerator Platform, London, UK"},{"name":"Royal Brompton & Harefield NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine","family":"Needham","sequence":"additional","affiliation":[{"name":"Clinical Trials Accelerator Platform, London, UK"},{"name":"Royal Brompton & Harefield NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Pao","sequence":"additional","affiliation":[{"name":"Clinical Trials Accelerator Platform, London, UK"},{"name":"Barts Health NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5164-789X","authenticated-orcid":false,"given":"Gary","family":"Ruiz","sequence":"additional","affiliation":[{"name":"Clinical Trials Accelerator Platform, London, UK"},{"name":"King\u2019s College Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahideh","family":"Safavi","sequence":"additional","affiliation":[{"name":"Clinical Trials Accelerator Platform, London, UK"},{"name":"Barts Health NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Saunders","sequence":"additional","affiliation":[{"name":"Clinical Trials Accelerator Platform, London, UK"},{"name":"Royal Brompton & Harefield NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Shafi","sequence":"additional","affiliation":[{"name":"Clinical Trials Accelerator Platform, London, UK"},{"name":"Barts Health NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1705-4780","authenticated-orcid":false,"given":"Nicholas J","family":"Simmonds","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Imperial College London, London, UK"},{"name":"Clinical Trials Accelerator Platform, London, UK"},{"name":"Royal Brompton & Harefield NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4954-8339","authenticated-orcid":false,"given":"Michael D","family":"Waller","sequence":"additional","affiliation":[{"name":"Clinical Trials Accelerator Platform, London, UK"},{"name":"King\u2019s College Hospital NHS Foundation Trust, London, UK"},{"name":"King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danie","family":"Watson","sequence":"additional","affiliation":[{"name":"Clinical Trials Accelerator Platform, London, UK"},{"name":"Barts Health NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7937-2728","authenticated-orcid":false,"given":"Gwyneth","family":"Davies","sequence":"additional","affiliation":[{"name":"Clinical Trials Accelerator Platform, London, UK"},{"name":"Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK"},{"name":"UCL Great Ormond Street Institute of Child Health, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"2026071304500824000_80.11.849.1","unstructured":"Cystic Fibrosis Trust . 2022 annual data report (version 8). 2023. Available: https:\/\/www.cysticfibrosis.org.uk\/sites\/default\/files\/2023-10\/CFT_2022_Annual_Data_Report_FINAL_v8.pdf"},{"key":"2026071304500824000_80.11.849.2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00080312"},{"key":"2026071304500824000_80.11.849.3","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2023.03.005","article-title":"How representative are clinical trial cohorts of the general CF population? Implications for trial planning","volume":"23","author":"Dobra","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2026071304500824000_80.11.849.4","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202205-0963OC"},{"key":"2026071304500824000_80.11.849.5","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202302-0310ST"},{"key":"2026071304500824000_80.11.849.6","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMsa2311809","article-title":"Implications of Race Adjustment in Lung-Function Equations","volume":"390","author":"Diao","year":"2024","journal-title":"N Engl J Med"},{"key":"2026071304500824000_80.11.849.7","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jcf.2024.03.013","article-title":"The impact of switching to race-neutral reference equations on FEV1 percent predicted among people with cystic fibrosis","volume":"23","author":"Rosenfeld","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2026071304500824000_80.11.849.8","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202202-0392OC"},{"key":"2026071304500824000_80.11.849.9","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201301-0153OC"},{"key":"2026071304500824000_80.11.849.10","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200911-1646OC"},{"key":"2026071304500824000_80.11.849.11","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S2213-2600(16)30121-7","article-title":"Efficacy and safety of lumacaftor\/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis","volume":"4","author":"Elborn","year":"2016","journal-title":"Lancet Respir Med"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2024-222652","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T02:27:05Z","timestamp":1783996025000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2024-222652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":11,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,10,15]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1136\/thorax-2024-222652"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2024-222652","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]}}}